Our finding may imply that structural MRI preserves the information of the APOE-ε4 effect on the brain structural deterioration, while there is no difference observed in neurocognitive performance between APOE-ε4 carriers and non-carriers for patients in the late stage of the AD spectrum. The gene discussed is APOE; the disease is Alzheimer disease.